Small Molecule Kinase Inhibitors : Market Research Report

Small Molecule Kinase Inhibitors

Published by: Global Industry Analysts

Published: Jul. 1, 2009 - 558 Pages

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS: Study Reliability and Reporting Limitations; Disclaimers; Data Interpretation & Reporting Level
II. EXECUTIVE SUMMARY: 1.INDUSTRY OVERVIEW; TABLE 1: CLINICAL PHASE TRANSITION PERCENTAGE FOR NOVEL KINASE INHIBITOR COMPOUNDS IN CLINICAL DEVELOPMENT - ALL DRUGS VS KINASE INHIBITORS, DURING THE PERIOD (1995-2007) (INCLUDES CORRESPONDING GRAPH/CHART); Developing Kinase Inhibitors; Rising Incidences of Cancer & Unmet Treatment Needs: A Prime Driver; Multi-Targeted Kinase Inhibitors: The Next Frontier; Single Vs Multi-Target Kinase Inhibitor Drugs; Spiraling Cost of Next Generation Cancer Drugs: A Cause for Concern; Table 3: Average Monthly Costs of Anti-Cancer Drugs (2007): Breakdown of Treatment Costs by Cancer Drug Brands - Rituxan, Erbitux, Revilimid, Avastin - High Dose, Avastin - Low Dose, Nexavar, Sutent, Herceptin, Gleevec, Tarceva, Tykerb, Iressa, Vectibix, Torisel and Targeted Therapies (In US$) for US, EU and Japan; Manufacturers Find Risk-Sharing, Rebating, & Contracting As Effective Antidotes; Financial-based Contracts; Implications for the Patient; Table 4: Oral Anticancer Drugs Covered in MedicarePart D Plans (2009): Percentage Share Breakdown of Plans, Which Require Prior Authorization, & Plans,Which Have Quantity Limits, by Drug Brand(includes corresponding Graph/Chart); Table 6: Placement of Select Oral Anticancer Drugs in the Drug Tier System Covered in Medicare Part D Plans for the Year 2009); Table 8: Change in Percentage of Co-insurance Amount for Leading Oral Cancer Therapies Under Standalone Prescription Drug Plans (PDPs) (During 2006 to 2009) - For Gleevec, Tarceva, Sutent, and Tykerb (includes corresponding Graph/Chart); Noteworthy Issues Related to Major Drugs: An Evaluation of Pros and Cons; TABLE 9: A REVIEW OF THE EFFECTIVENESS OF SPRYCEL AND TASIGNA IN THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA (CML): PERCENTAGE BREAKDOWN OF EFFICIENCY LEVELS BY CLINICAL ENDPOINTS AS A MEASURE OF PATIENT RESPONSE (INCLUDES CORRESPONDING GRAPH/CHART); Nexavar Shows Promise in the HCC Market; Key Statistical Findings; Table 12: Global Sales of Iressa in the Treatment of NSCLC (2009E): Percentage Breakdown by First Line NSCLC, Second Line NSCLC and Third Line NSCLC (includes corresponding Graph/Chart); Table 14: Global Sales of Nexavar (2009 & 2015P): Percentage Breakdown of Dollar Sales by Geographic Region/Country - United States, Europe, and Rest of World (includes corresponding Graph/Chart); Table 16: Canadian Healthcare Market (2007): Breakdown of Total Payments Made by Private and Public Insurers Towards Take Home Cancer Drugs (THCDs) by Select Drug Brands - Gleevec, Tarceva, Sutent, Nexavar, Sprycel, and Iressa (In US$ million) (includes corresponding Graph/Chart); Outlook; Key Small Molecule pKis Under Different Stages of Clinical Trials; Pharmaceutical Industry: Review of the Present Scenario; Table 18: World Pharmaceutical Industry (2007):BRIC Nations (Brazil, Russia, India and China), &United States Ranked by Percentage Growth(includes corresponding Graph/Chart); Landmark Deals Announced or Completed by Pharma andBiotech Companies Engaged in Developing KinaseInhibitor Drugs, During the Year 2008 & 2009; Biotech Bankruptcies: Casualties On the Rise; 2.KINASE INHIBITOR DRUGS: AN OVERVIEW; Approvals; Related Clinical Trials; Dasatinib (SPRYCEL® - Bristol-Myers Squibb); Approvals; Approvals; Approvals; Small Molecule Kinase Inhibitor Drugs In Pipeline; Cediranib (Recentin™ - AstraZeneca); Bosutinib (Wyeth); CP-690550 (Pfizer); 3.KINASE INHIBITORS: A RUDIMENTARYOVERVIEW; Comparison of Various Pharmacological andPharmacokinetic Parameters For Small Molecules and Monoclonal Antibodies; Receptor Tyrosine Kinase (RTK) Inhibitors; FLT3 (Fms-like tyrosine kinase 3) Inhibitors; Janus (JAK) Kinase Inhibitors; CDK (Cyclin Dependent Kinase) Inhibitors; MAP (Mitogen activated protein) / MEK Inhibitors; 4.PRODUCT LAUNCHES; AVEO Identifies New Indication for AV-951 Triple VEGF Receptor Inhibitor; Millennium Commences Phase II Trials for MLN8237; Cell Biosciences Unveils First Kits for Oncoprotein Analysis; KAI and BMS Forms Global Alliance on KAI-9803; Oncothyreon Commences Phase I PX-866 Clinical Trial; Onyx and Bayer Secure FDA and EC Approval for Nexavar®; New Plk1 Kinase Inhibitor BI 2536 Developed; 5.RECENT INDUSTRY ACTIVITY; Sanofi-Aventis to acquire Bipar Sciences; Eli Lilly Acquires SGX Pharmaceuticals; Antisoma Acquires Xanthus; ACT Biotech Agrees to Acquire the Under Clinical Stage Oncology Portfolio of Bayer Healthcare; Cellzome and GlaxoSmithKline Form Alliance; Aegera Therapeutics Takes over LymphoSign; Pfizer Collaborate with Rigel, to Develop R343 as Treatment for Allergic Asthma; 6.FOCUS ON SELECT PLAYERS; Bristol-Myers Squibb Company (US); F. Hoffmann-La Roche, Ltd. (Switzerland); KAI Pharmaceuticals, Inc (USA); Mitsubishi Tanabe Pharma Corporation (Japan); Pfizer, Inc. (US); S*Bio Pte Ltd (Singapore); Wyeth (US); 7.GLOBAL MARKET PERSPECTIVE; Table 20: World 10-Year Perspective for Kinase Inhibitors by Product Segment - Percentage Breakdown of Dollar Sales for Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, Tykerb/Tyverb and Others For Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
III. COMPETITIVE LANDSCAPE: Total Companies Profiled:; Region/Country Players; The United States; Canada; Japan; Europe; Asia-Pacific (Excluding Japan)

Abstract

This report analyzes the Global Market for Small Molecule Kinase Inhibitors in Millions of US$ by the following Product Segments: Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, Tykerb/Tyverb, and Others. Annual forecasts are provided for the period 2006 through 2015. The report profiles 83 companies including many key and niche players worldwide such as Amgen, Inc., Asahi Kasei Pharma Corporation, AstraZeneca plc., Bayer Schering Pharma AG, Bristol-Myers Squibb Company,.Celgene Corporation, Exelixis, Inc., F. Hoffmann-La Roche, Ltd., Chugai Pharmaceutical Co, Ltd., Genentech, Inc., GlaxoSmithKline plc., KAI Pharmaceuticals, Inc., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis International AG, Onyx Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc., Pfizer, Inc., Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc, S*Bio Pte Ltd., Sanofi-Aventis, Vertex Pharmaceuticals Incorporated, and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Titles available via "online download" are not affected by this and are still delivered to your reading room immediately.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/14/2012 - 30

Small Molecule Kinase Inhibitors

Table of Contents

Abstract